Previous Article Specialty Medicines Next Article New Therapeutic Entities (NTEs) Generics R&D In our generics R&D, there is much more to generics than meets the eye. We bring creativity, innovative thinking, and the ability to analyze, formulate and execute in a timely and effective manner. This is particularly true in the area of complex, hard to develop generics, where we deliver a real competitive edge. Share on Facebook Share on LinkedIn Share on Twitter ✉ Generics. More than Meets the EyeOur generics R&D is closely integrated with our extensive clinical expertise in developing specialty and OTC products. This makes us the only global pharmaceutical company that has an integrated generic and specialty (branded) R&D capability.With generics R&D and specialty R&D working hand-in-hand, this unique combination of strengths, capabilities and skills enables new ideas and improved innovation. Proud of Our Heritage, Inspired by New PossibilitiesGreat medicines start with great minds. Our R&D group maintains a mindset of exceptional professionalism, matched by speed, flexibility and a desire for value creation for patients, healthcare providers and customers worldwide. Our strengths in generics R&D are directed at fostering discovery and innovation. Unmatched TechnologyOur generics R&D capabilities have expanded beyond tablets, capsules, liquids, ointments and creams to a broad range of dosage forms and delivery systems. These include sterile devices, modified release parenteral injectables, transdermal patches and films, and nasal suspensions. Our generics R&D group continues to develop an array of special delivery technologies ranging from extended-release to drug device combinations. More Value for More People Around the WorldWe’re working around the world, and around the clock to deliver affordable medicines in a multitude of therapeutic areas. Our generics R&D activities are carried out in development centers in the United States, Europe, Latin America, Israel, Japan and India. We are focused on the development of complex, difficult to produce, high-value treatment options to address the unmet needs of patients and improve health outcomes. Did You Know? We are the leading generics company in the world: • Across the world approximately 200 million patients per year are helped by our generic medicines• Approximately 1 out of every 8 US pharmaceutical prescriptions is filled with a Teva product*• We are the largest single provider of medicines to the UK’s NHS, saving £2.8 billion from the NHS drug bill. • Teva markets over 1,000 generic molecules and has hundreds of molecules in development• 73 billion pills a year are manufactured by Teva for patients across the world* IMS Health NPA MAT June 2014.
Generics. More than Meets the EyeOur generics R&D is closely integrated with our extensive clinical expertise in developing specialty and OTC products. This makes us the only global pharmaceutical company that has an integrated generic and specialty (branded) R&D capability.With generics R&D and specialty R&D working hand-in-hand, this unique combination of strengths, capabilities and skills enables new ideas and improved innovation. Proud of Our Heritage, Inspired by New PossibilitiesGreat medicines start with great minds. Our R&D group maintains a mindset of exceptional professionalism, matched by speed, flexibility and a desire for value creation for patients, healthcare providers and customers worldwide. Our strengths in generics R&D are directed at fostering discovery and innovation. Unmatched TechnologyOur generics R&D capabilities have expanded beyond tablets, capsules, liquids, ointments and creams to a broad range of dosage forms and delivery systems. These include sterile devices, modified release parenteral injectables, transdermal patches and films, and nasal suspensions. Our generics R&D group continues to develop an array of special delivery technologies ranging from extended-release to drug device combinations. More Value for More People Around the WorldWe’re working around the world, and around the clock to deliver affordable medicines in a multitude of therapeutic areas. Our generics R&D activities are carried out in development centers in the United States, Europe, Latin America, Israel, Japan and India. We are focused on the development of complex, difficult to produce, high-value treatment options to address the unmet needs of patients and improve health outcomes. Did You Know? We are the leading generics company in the world: • Across the world approximately 200 million patients per year are helped by our generic medicines• Approximately 1 out of every 8 US pharmaceutical prescriptions is filled with a Teva product*• We are the largest single provider of medicines to the UK’s NHS, saving £2.8 billion from the NHS drug bill. • Teva markets over 1,000 generic molecules and has hundreds of molecules in development• 73 billion pills a year are manufactured by Teva for patients across the world* IMS Health NPA MAT June 2014.